SCHEMBL2959933

SCHEMBL2959933

Clc1ccc(C2=C(CN3CCN(c4cc[c]cc4)CC3)CCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.47
MAPT P10636 3/20 0.46
DRD4 P21917 5/20 0.45
DRD3 P35462 3/20 0.43
BCL2 P10415 2/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 1/20 0.42
LSS P48449 1/20 0.42
DRD2 P14416 2/20 0.41
KMT2A Q03164 2/20 0.40
LMNA P02545 2/20 0.40
DRD5 P21918 1/20 0.40
CHKA P35790 1/20 0.40
MEN1 O00255 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2975749 0.99 BCL2L1 (0.47) BCL2L1MAPTDRD4DRD3BCL2
SCHEMBL2970947 0.83 BCL2 (0.46) BCL2L1MAPTDRD4DRD3BCL2
SCHEMBL1540932 0.82 BCL2L1 (0.50) BCL2L1MAPTDRD4DRD3BCL2
SCHEMBL1540934 0.82 BCL2L1 (0.50) BCL2L1MAPTDRD4DRD3BCL2
SCHEMBL2973314 0.82 BCL2L1 (0.60) BCL2L1DRD4BCL2
SCHEMBL1540416 0.81 BCL2L1 (0.49) BCL2L1MAPTDRD4DRD3BCL2
SCHEMBL1540221 0.81 BCL2L1 (0.49) BCL2L1MAPTDRD4DRD3BCL2
SCHEMBL1540223 0.81 BCL2L1 (0.49) BCL2L1MAPTDRD4DRD3BCL2
SCHEMBL1540415 0.81 BCL2L1 (0.49) BCL2L1MAPTDRD4DRD3BCL2
SCHEMBL29312875 0.81 BCL2L1 (0.49) BCL2L1MAPTDRD4DRD3BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888543-B1 APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-08-01 EP disclosed
US-7777076-B2 Macrocyclic inhibitors of BCL proteins ABBOTT LABORATORIES (US) 2010-08-17 US disclosed
US-20080194691-A1 Apoptosis Promoters ABBOTT LABORATORIES (US) 2008-08-14 US disclosed
EP-1888543-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2008-02-20 EP disclosed
WO-2006127364-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194691-A1 Apoptosis Promoters BAX, BCL2, BCOR BCL2L1 6/4885MAPT 4484/4885DRD4 3815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.